Incanthera, the dermatology and oncology technology company quoted on the AQSE Growth Market, appeared among the most volatile UK stocks on 23 September 2026. The listing follows a summer of acquisition, boardroom change and a Supply deal with LED device maker iSmart that the company describes as its first contracted recurring revenue.
Incanthera plc (LSE:INC) was among the most volatile UK stocks on 23 September 2026. Since early June the company has acquired a Swiss skincare Brand for shares, replaced its chief executive and chairman and, on 7 September, announced an exclusive supply agreement with UK LED skincare device maker iSmart Developments.
Incanthera began as a spin-out from the University of Bradford's Institute of Cancer Therapeutics and now sells the Skin + CELL and énielle skincare ranges. With a small market value, a share price in low single-digit pence and thin trading, news flow of this kind can move the shares sharply in either direction.
Why Incanthera (INC) Is in Focus
The immediate catalyst appears to be the iSmart agreement. Under the deal, announced on 7 September 2026, Incanthera will supply bioactive creams to be bundled with iSmart's LED light therapy devices, with annual contracted minimum orders. The value of those minimum orders was not disclosed.
The market reaction was pronounced. In the week to 13 September, Incanthera shares gained 26.01% to 1.45p.
What Does Incanthera Do?
Incanthera describes itself as a dermatology and oncology technology business. Its roots lie in cancer research, but its commercial emphasis has shifted towards premium skincare built on formulation expertise and intellectual property from that science. Skin + CELL was launched through a direct-to-consumer website in August 2025.
In June 2026 the group added énielle, a Swiss serum brand based on lectin technology. Management now positions the two ranges as a "protect by day, repair by night" routine, with énielle for daytime use and Skin + CELL focused on cellular repair and UV protection in the evening. The strategy is now moving towards partnership-led supply, licensing and retail distribution.
What Has Been Happening Recently?
Key announcements this year include:
- 31 March 2026: a commercial update disclosed that Skin + CELL sold 177 units in the first quarter of 2026, generating £12,400 of revenue, below initial expectations.
- 4 June 2026: Incanthera agreed to acquire the énielle Assets from GIFFRIES Technology AG for 54 million shares at 2p each, with 13,793,800 issued immediately and 40,206,200 deferred and contingent on performance over six months. Stuart Robertson became chief executive, Dr Simon Ward became chief scientific officer and Tim McCarthy stepped down as executive chairman. Mr Robertson also provided a £250,000 convertible Loan Facility at 2p, drawing £100,000 immediately.
- 13 July 2026: the company confirmed completion of the énielle deal, appointed Laura Brogden as chief financial officer and Caroline Murray as non-executive chair, and targeted at least a 50% reduction in cash compensation, with directors paid largely in Options until profitability.
- 7 September 2026: the iSmart supply agreement was announced.
What Are the Numbers Saying?
Incanthera's financial footprint is small. Its half-year report, published on 11 December 2025 and covering the six months to 30 September 2025, showed revenue of £6,000 against nil a year earlier, a loss before tax of £888,000 (2024: £695,000) and a loss per share of 0.69p. Cash at the period end was £215,000, compared with £1.058m twelve months earlier, after net share issue proceeds of £448,000 during the half.
The first-quarter 2026 sales figure of £12,400 shows how early the commercial journey remains. Following admission of the énielle consideration shares on 10 June 2026, total voting rights stood at 151,731,874 shares. The company said énielle came with around 6,000 finished units available for sale.
Why Is the Share Price Attracting Attention?
The facts: revenue is modest, and the company has issued Equity and arranged convertible funding at 2p. The iSmart agreement introduces contracted minimum orders, and Incanthera says iSmart supplies around one million LED devices a year under brands including Omnilux and faceLITE. In a split-face consumer trial run by iSmart, all participants rated the cream-plus-LED combination as improved against baseline.
Interpretations differ. One possible interpretation of the recent rise is that some investors view a supply deal with an established device maker as validation of the formulation work. Others may focus on the undisclosed value of the minimum orders, the outstanding deferred consideration shares and potential dilution from the convertible facility. In a thinly traded share, modest shifts in Demand can produce large percentage swings.
How Does the AQSE Growth Market Context Matter?
Incanthera is quoted on the AQSE Growth Market, operated by Aquis Stock Exchange, rather than on AIM or the London Stock Exchange Main Market, and it is not a constituent of any FTSE index. AQSE caters for early-stage and smaller companies, many with limited daily trading, where bid-offer spreads can be wide relative to the share price and a single announcement can attract unusually heavy volume.
There is no evidence that broader market movements drove Incanthera's recent trading; the reported weekly gain coincided with company-specific news.
What Could Investors Watch Next?
Items that could influence sentiment include:
- Annual results: last year's final results were released on 30 September 2025; audited figures for the year to 31 March 2026 would give the first full-year view since the strategy reset.
- iSmart orders: any disclosure of order volumes or revenue under the contracted minimums.
- énielle deferred shares: whether the performance conditions attached to the 40,206,200 deferred consideration shares are met over the six-month period.
- Distribution and product pipeline: progress on the retail distribution talks flagged in March and on the planned SPF range.
- Funding: further drawdowns under Mr Robertson's convertible facility or any new Capital raising.
The Bottom Line
Incanthera's appearance among the most volatile UK stocks on 23 September reflects a company in rapid transition. In little more than three months it has acquired a second brand, overhauled its board, set out cost cuts and signed an exclusive supply deal with iSmart. The shares responded strongly in the week after that deal. Yet the underlying numbers remain small: first-quarter 2026 sales were £12,400 and cash at the last reported half-year end was £215,000. The key questions now are whether iSmart orders translate into meaningful revenue, how the énielle performance shares are settled and what the annual results reveal about funding. Volatility cuts both ways, and past price swings offer no guide to future direction.






Please wait processing your request...